The DOI matches its Crossref record; 125 of the 125 references it cites were found in a registry or an index.
Glypican‐3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment
Abstract
Liver cancer is the second leading cause of cancer‐related deaths, and hepatocellular carcinoma (HCC) is the most common type. Therefore, molecular targets are urgently required for the early detection of HCC and the development of novel therapeutic approaches. Glypican‐3 (GPC3), an oncofetal proteoglycan anchored to the cell membrane, is normally detected in the fetal liver but not in the healthy adult liver. However, in HCC patients, GPC3 is overexpressed at both the gene and protein levels, and its expression predicts a poor prognosis. Mechanistic studies have revealed that GPC3 functions in HCC progression by binding to molecules such as Wnt signaling proteins and growth factors. Moreover, GPC3 has been used as a target for molecular imaging and therapeutic intervention in HCC. To date, GPC3‐targeted magnetic resonance imaging, positron emission tomography, and near‐infrared imaging have been investigated for early HCC detection, and various immunotherapeutic protocols targeting GPC3 have been developed, including the use of humanized anti‐GPC3 cytotoxic antibodies, treatment with peptide/DNA vaccines, immunotoxin therapies, and genetic therapies. In this review, we summarize the current knowledge regarding the structure, function, and biology of GPC3 with a focus on its clinical potential as a diagnostic molecule and a therapeutic target in HCC immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Forner, A., Llovet, J. M., & Bruix, J. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61347-0 · Cited by 4,022
Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis
Yang, J., Mani, S. A., Donaher, J. L., Ramaswamy, S., Itzykson, R. A., Come, C., Savagner, P., Gitelman, I., Richardson, A., & Weinberg, R. A. (2004) · Cell · doi:10.1016/j.cell.2004.06.006 · Cited by 3,855
Tumour-educated macrophages promote tumour progression and metastasis
Pollard, J. W. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1256 · Cited by 3,367
Epithelial–mesenchymal transitions in development and pathologies
Thiery, J. P. (2003) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2003.10.006 · Cited by 1,704
TGFβ signalling: a complex web in cancer progression
Ikushima, H., & Miyazono, K. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2853 · Cited by 1,173
Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma
Capurro, M., Wanless, I. R., Sherman, M., Deboer, G., Shi, W., Miyoshi, E., & Filmus, J. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00689-9 · Cited by 917
Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome
Pilia, G., Hughes-Benzie, R. M., MacKenzie, A., Baybayan, P., Chen, E. Y., Huber, R., Neri, G., Cao, A., Forabosco, A., & Schlessinger, D. (1996) · Nature Genetics · doi:10.1038/ng0396-241 · Cited by 761
Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver
Lu, L., Li, Y., Kim, S. M., Bossuyt, W., Liu, P., Qiu, Q., Wang, Y., Halder, G., Finegold, M. J., Lee, J.-S., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0911427107 · Cited by 721
Carcinoma Invasion and Metastasis: A Role for Epithelial-Mesenchymal Transition?
Thompson, E. W., & Newgreen, D. F. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0616 · Cited by 667
Filmus, J., Capurro, M., & Rast, J. (2008) · Genome Biology · doi:10.1186/gb-2008-9-5-224 · Cited by 556
Pastan, I., Hassan, R., FitzGerald, D. J., & Kreitman, R. J. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1891 · Cited by 528
Lee, K.-P., Lee, J.-H., Kim, T.-S., Kim, T.-H., Park, H.-D., Byun, J.-S., Kim, M.-C., Jeong, W.-I., Calvisi, D. F., Kim, J.-M., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912203107 · Cited by 493
Glypican-3 Promotes the Growth of Hepatocellular Carcinoma by Stimulating Canonical Wnt Signaling
Capurro, M. I., Xiang, Y.-Y., Lobe, C., & Filmus, J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4244 · Cited by 469
Notum deacylates Wnt proteins to suppress signalling activity
Kakugawa, S., Langton, P. F., Zebisch, M., Howell, S. A., Chang, T.-H., Liu, Y., Feizi, T., Bineva, G., O’Reilly, N., Snijders, A. P., et al. (2015) · Nature · doi:10.1038/nature14259 · Cited by 446
Glypicans: proteoglycans with a surprise
Filmus, J., & Selleck, S. B. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13712 · Cited by 441
Glypican-3 as a Serum Marker for Hepatocellular Carcinoma
Capurro, M., & Filmus, J. (2005) · Cancer Research · doi:10.1158/0008-5472.372.65.1 · Cited by 432
Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker
Nakatsura, T., Yoshitake, Y., Senju, S., Monji, M., Komori, H., Motomura, Y., Hosaka, S., Beppu, T., Ishiko, T., Kamohara, H., et al. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)00908-2 · Cited by 430
Di Tommaso, L., Franchi, G., Park, Y. N., Fiamengo, B., Destro, A., Morenghi, E., Montorsi, M., Torzilli, G., Tommasini, M., Terracciano, L., et al. (2007) · Hepatology · doi:10.1002/hep.21531 · Cited by 427
Kaposi-Novak, P. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27236 · Cited by 398
Llovet, J. M., Chen, Y., Wurmbach, E., Roayaie, S., Fiel, M. I., Schwartz, M., Thung, S. N., Khitrov, G., Zhang, W., Villanueva, A., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.09.014 · Cited by 386
Capurro, M. I., Xu, P., Shi, W., Li, F., Jia, A., & Filmus, J. (2008) · Developmental Cell · doi:10.1016/j.devcel.2008.03.006 · Cited by 364
Di Tommaso, L., Destro, A., Seok, J. Y., Balladore, E., Terracciano, L., Sangiovanni, A., Iavarone, M., Colombo, M., Jang, J. J., Yu, E., et al. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2008.11.014 · Cited by 322
Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular Carcinoma
Gao, H., Li, K., Tu, H., Pan, X., Jiang, H., Shi, B., Kong, J., Wang, H., Yang, S., Gu, J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1170 · Cited by 313
Sawada, Y., Yoshikawa, T., Nobuoka, D., Shirakawa, H., Kuronuma, T., Motomura, Y., Mizuno, S., Ishii, H., Nakachi, K., Konishi, M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3044 · Cited by 302
Hippo, Y., Watanabe, K., Watanabe, A., Midorikawa, Y., Yamamoto, S., Ihara, S., Tokita, S., Iwanari, H., Ito, Y., Nakano, K., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2191 · Cited by 297
Pez, F., Lopez, A., Kim, M., Wands, J. R., Caron de Fromentel, C., & Merle, P. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.07.001 · Cited by 294
Zhu, Z.-W., Friess, H., Wang, L., Abou-Shady, M., Zimmermann, A., Lander, A. D., Korc, M., Kleeff, J., & Büchler, M. W. (2001) · Gut · doi:10.1136/gut.48.4.558 · Cited by 291
Glypican‐3 expression is correlated with poor prognosis in hepatocellular carcinoma
Shirakawa, H., Suzuki, H., Shimomura, M., Kojima, M., Gotohda, N., Takahashi, S., Nakagohri, T., Konishi, M., Kobayashi, N., Kinoshita, T., et al. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01206.x · Cited by 279
Baumhoer, D., Tornillo, L., Stadlmann, S., Roncalli, M., Diamantis, E. K., & Terracciano, L. M. (2008) · American Journal of Clinical Pathology · doi:10.1309/hcqwpwd50xhd2dw6 · Cited by 262
(1997) · PubMed · Cited by 239
Glypican‐3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP‐7 signaling
Midorikawa, Y., Ishikawa, S., Iwanari, H., Imamura, T., Sakamoto, H., Miyazono, K., Kodama, T., Makuuchi, M., & Aburatani, H. (2003) · International Journal of Cancer · doi:10.1002/ijc.10856 · Cited by 238
WANG, X., DEGOS, F., DUBOIS, S., TESSIORE, S., ALLEGRETTA, M., GUTTMANN, R., JOTHY, S., BELGHITI, J., BEDOSSA, P., & PARADIS, V (2006) · Human Pathology · doi:10.1016/j.humpath.2006.05.016 · Cited by 228
Glypicans in growth control and cancer
Filmus, J. (2001) · Glycobiology · doi:10.1093/glycob/11.3.19r · Cited by 226
Ueki, T., Fujimoto, J., Suzuki, T., Yamamoto, H., & Okamoto, E. (1997) · Hepatology · doi:10.1002/hep.510250413 · Cited by 226
The Loss of Glypican-3 Induces Alterations in Wnt Signaling
Song, H. H., Shi, W., Xiang, Y.-Y., & Filmus, J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m410090200 · Cited by 215
Lai, J., Sandhu, D. S., Yu, C., Han, T., Moser, C. D., Jackson, K. K., Guerrero, R. B., Aderca, I., Isomoto, H., Garrity‐Park, M. M., et al. (2008) · Hepatology · doi:10.1002/hep.22202 · Cited by 208
Zhu, A. X., Gold, P. J., El-Khoueiry, A. B., Abrams, T. A., Morikawa, H., Ohishi, N., Ohtomo, T., & Philip, P. A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2616 · Cited by 193
Tremosini, S., Forner, A., Boix, L., Vilana, R., Bianchi, L., Reig, M., Rimola, J., Rodríguez-Lope, C., Ayuso, C., Solé, M., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-301862 · Cited by 188
De Cat, B., Muyldermans, S.-Y., Coomans, C., Degeest, G., Vanderschueren, B., Creemers, J., Biemar, F., Peers, B., & David, G. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200302152 · Cited by 186
Traister, A., Shi, W., & Filmus, J. (2008) · Biochemical Journal · doi:10.1042/bj20070511 · Cited by 183
Feng, M., Gao, W., Wang, R., Chen, W., Man, Y.-G., Figg, W. D., Wang, X. W., Dimitrov, D. S., & Ho, M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1217868110 · Cited by 183
Sawada, Y., Yoshikawa, T., Ofuji, K., Yoshimura, M., Tsuchiya, N., Takahashi, M., Nobuoka, D., Gotohda, N., Takahashi, S., Kato, Y., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1129483 · Cited by 178
glypican-3 Controls Cellular Responses to Bmp4 in Limb Patterning and Skeletal Development
Paine-Saunders, S., Viviano, B. L., Zupicich, J., Skarnes, W. C., & Saunders, S. (2000) · Developmental Biology · doi:10.1006/dbio.2000.9831 · Cited by 177
Komori, H., Nakatsura, T., Senju, S., Yoshitake, Y., Motomura, Y., Ikuta, Y., Fukuma, D., Yokomine, K., Harao, M., Beppu, T., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2267 · Cited by 175
Glypican-3 binds to frizzled and plays a direct role in the stimulation of canonical Wnt signaling
Capurro, M., Martin, T., Shi, W., & Filmus, J. (2014) · Journal of Cell Science · doi:10.1242/jcs.140871 · Cited by 172
Anti–Glypican 3 Antibody as a Potential Antitumor Agent for Human Liver Cancer
Ishiguro, T., Sugimoto, M., Kinoshita, Y., Miyazaki, Y., Nakano, K., Tsunoda, H., Sugo, I., Ohizumi, I., Aburatani, H., Hamakubo, T., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1973 · Cited by 168
Deregulation of Hippo kinase signalling in Human hepatic malignancies
Li, H., Wolfe, A., Septer, S., Edwards, G., Zhong, X., Bashar Abdulkarim, A., Ranganathan, S., & Apte, U. (2012) · Liver International · doi:10.1111/j.1478-3231.2011.02646.x · Cited by 168
Gao, W., Kim, H., Feng, M., Phung, Y., Xavier, C. P., Rubin, J. S., & Ho, M. (2014) · Hepatology · doi:10.1002/hep.26996 · Cited by 164
Gao, W., Tang, Z., Zhang, Y., Feng, M., Qian, M., Dimitrov, D. S., & Ho, M. (2015) · Nature Communications · doi:10.1038/ncomms7536 · Cited by 155
Glypican-5 stimulates rhabdomyosarcoma cell proliferation by activating Hedgehog signaling
Li, F., Shi, W., Capurro, M., & Filmus, J. (2011) · The Journal of Cell Biology · doi:10.1083/jcb.201008087 · Cited by 150
Paths of FGFR-driven tumorigenesis
Acevedo, V. D., Ittmann, M., & Spencer, D. M. (2009) · Cell Cycle · doi:10.4161/cc.8.4.7657 · Cited by 147
Abou-Alfa, G. K., Puig, O., Daniele, B., Kudo, M., Merle, P., Park, J.-W., Ross, P., Peron, J.-M., Ebert, O., Chan, S., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.04.004 · Cited by 137
Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma
Haruyama, Y., & Kataoka, H. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i1.275 · Cited by 136
Hughes-Benzie, R., Pilia, G., Xuan, J. Y., Hunter, A. G. W., Chen, E., Golabi, M., Hurst, J. A., Kobori, J. A., Marymee, K., Pagon, R. A., et al. (1996) · American Journal of Medical Genetics · doi:10.1002/(sici)1096-8628(19961211)66:2<227::aid-ajmg20>3.0.co;2-u · Cited by 134
OCI-5/Rat Glypican-3 Binds to Fibroblast Growth Factor-2 but Not to Insulin-like Growth Factor-2
Song, H. H., Shi, W., & Filmus, J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.12.7574 · Cited by 133
Lai, J.-P., Oseini, A. M., Moser, C. D., Yu, C., Elsawa, S. F., Hu, C., Nakamura, I., Han, T., Aderca, I., Isomoto, H., et al. (2010) · Hepatology · doi:10.1002/hep.23848 · Cited by 124
Veugelers, M. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.9.1321 · Cited by 123
Hara, H., Takahashi, T., Serada, S., Fujimoto, M., Ohkawara, T., Nakatsuka, R., Harada, E., Nishigaki, T., Takahashi, Y., Nojima, S., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.183 · Cited by 119
Expression pattern of glypican-3 (GPC3) during human embryonic and fetal development.
Iglesias, B. V., Centeno, G., Pascuccelli, H., Ward, F., Peters, M. G., Filmus, J., Puricelli, L., & Joffé, E. B. D. K. (2008) · PubMed · doi:10.14670/hh-23.1333 · Cited by 114
Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells
Nakano, K., Orita, T., Nezu, J., Yoshino, T., Ohizumi, I., Sugimoto, M., Furugaki, K., Kinoshita, Y., Ishiguro, T., Hamakubo, T., et al. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.11.033 · Cited by 111
Kawata, H., Yamada, K., Shou, Z., Mizutani, T., Yazawa, T., Yoshino, M., Sekiguchi, T., Kajitani, T., & Miyamoto, K. (2003) · Biochemical Journal · doi:10.1042/bj20030171 · Cited by 109
Drug delivery system targeting advanced hepatocellular carcinoma: Current and future
Zhang, X., Ng, H. L. H., Lü, A., Lin, C., Zhou, L., Lin, G., Zhang, Y., Yang, Z., & Zhang, H. (2016) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2015.12.381 · Cited by 108
MiR‐219‐5p inhibits hepatocellular carcinoma cell proliferation by targeting glypican‐3
Huang, N., Lin, J., Ruan, J., Su, N., Qing, R., Liu, F., He, B., Cheng-wei, L., Zheng, D., & Luo, R. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.02.017 · Cited by 105
Soluble glypican 3 inhibits the growth of hepatocellular carcinoma in vitro and in vivo
Zittermann, S. I., Capurro, M., Shi, W., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24941 · Cited by 103
Maurel, M., Jalvy, S., Ladeiro, Y., Combe, C., Vachet, L., Sagliocco, F. A., Bioulac‐Sage, P., Pitard, V., Jacquemin‐Sablon, H., Zucman‐Rossi, J., et al. (2012) · Hepatology · doi:10.1002/hep.25994 · Cited by 102
Role for Amplification and Expression of Glypican-5 in Rhabdomyosarcoma
Williamson, D., Selfe, J., Gordon, T., Lu, Y., Pritchard‐Jones, K., Murai, K., Jones, P. H., Workman, P., & SHIPLEY, J. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1650 · Cited by 101
Cottereau, E., Mortemousque, I., Moizard, M., Bürglen, L., Lacombe, D., Gilbert‐Dussardier, B., Sigaudy, S., Boute, O., David, A., Faivre, L. O., et al. (2013) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.31360 · Cited by 100
Nakatsura, T., Komori, H., Kubo, T., Yoshitake, Y., Senju, S., Katagiri, T., Furukawa, Y., Ogawa, M., Nakamura, Y., & Nishimura, Y. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1177 · Cited by 97
Dargel, C., Bassani‐Sternberg, M., Hasreiter, J., Zani, F., Bockmann, J., Thiele, F., Bohne, F., Wisskirchen, K., Wilde, S., Sprinzl, M. F., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.055 · Cited by 96
Sun, C. K.-W., Chua, M., He, J., & Samuel, K. S. (2011) · Neoplasia · doi:10.1593/neo.11664 · Cited by 96
Glypican-3 is a potential prognostic biomarker for hepatocellular carcinoma after curative resection
Fu, S., Qi, C.-Y., Xiao, W., Li, S., Peng, B., & Liang, L. (2013) · Surgery · doi:10.1016/j.surg.2013.02.014 · Cited by 88
Kowalik, M. A., Saliba, C., Pibiri, M., Perra, A., Ledda-Columbano, G. M., Sarotto, I., Ghiso, E., Giordano, S., & Columbano, A. (2011) · Hepatology · doi:10.1002/hep.24289 · Cited by 86
Morford, L. A., Davis, C., Jin, L., Dobierzewska, A., Peterson, M. L., & Spear, B. T. (2007) · Hepatology · doi:10.1002/hep.21825 · Cited by 85
Oncogenic activation of glypican-3 by c-Myc in human hepatocellular carcinoma
Li, L., Jin, R., Zhang, X., Lv, F., Liu, L., Liu, D., Liu, K., Li, N., & Chen, D. (2012) · Hepatology · doi:10.1002/hep.25891 · Cited by 85
Sawada, Y., Yoshikawa, T., Shimomura, M., Iwama, T., Endo, I., & Nakatsura, T. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2737 · Cited by 82
Jia, X., Liu, J., Gao, Y., Huang, Y. L., & Zhi, D. (2014) · Archives of Medical Research · doi:10.1016/j.arcmed.2014.11.002 · Cited by 81
Ikeda, M., Ohkawa, S., Okusaka, T., Mitsunaga, S., Kobayashi, S., Morizane, C., Suzuki, I., Yamamoto, S., & Furuse, J. (2014) · Cancer Science · doi:10.1111/cas.12368 · Cited by 77
Gao, W., Kim, H., & Ho, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0137664 · Cited by 76
Nault, J., Guyot, E., Laguillier, C., Chevret, S., Ganne‐Carrié, N., Nkontchou, G., Beaugrand, M., Séror, O., Trinchet, J., Coelho, J., et al. (2013) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-13-0179 · Cited by 75
Wang, K., Kievit, F. M., Sham, J. G., Jeon, M., Stephen, Z. R., Bakthavatsalam, A., Park, J. O., & Zhang, M. (2015) · Small · doi:10.1002/smll.201501985 · Cited by 75
Feng, J., Zhu, R., Chang, C. H., Yu, L., Cao, F., Zhu, G., Chen, F., Xia, H., Lv, F., Zhang, S., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151501 · Cited by 73
Novel Glypican-3-Binding Peptide for in Vivo Hepatocellular Carcinoma Fluorescent Imaging
Zhu, D., Qin, Y., Wang, J., Zhang, L., Zou, S., Zhu, X., & Zhu, L. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00030 · Cited by 70
Takai, H., Ashihara, M., Ishiguro, T., Terashima, H., Watanabe, T., Kato, A., & Suzuki, M. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.24.9985 · Cited by 69
Su, N., Chen, B., Huang, N., Peng, S., Ding, Y., Ye, X., Zeng, F., Zheng, D., & Luo, R. (2011) · Molecular Biology Reports · doi:10.1007/s11033-011-0745-y · Cited by 68
Yang, J. D., Sun, Z., Hu, C., Lai, J., Dove, R., Nakamura, I., Lee, J., Thorgeirsson, S. S., Kang, K. J., Chu, I., et al. (2010) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20838 · Cited by 68
Glypican-1 in exosomes as biomarker for early detection of pancreatic cancer.
Herreros‐Villanueva, M., & Bujanda, L. (2016) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2015.10.39 · Cited by 67
α3 Chains of type V collagen regulate breast tumour growth via glypican-1
Huang, G., Ge, G., Izzi, V., & Greenspan, D. S. (2017) · Nature Communications · doi:10.1038/ncomms14351 · Cited by 66
Chen, I., Ariizumi, S., Nakano, M., & Yamamoto, M. (2013) · Journal of Gastroenterology · doi:10.1007/s00535-013-0793-2 · Cited by 65
Ng, A., Wong, M., Viviano, B. L., Erlich, J. M., Alba, G. A., Pflederer, C., Jay, P. Y., & Saunders, S. (2009) · Developmental Biology · doi:10.1016/j.ydbio.2009.08.029 · Cited by 64
Wong, K.-F., Liu, A. M., Hong, W., Xu, Z., & Luk, J. M. (2016) · Oncotarget · doi:10.18632/oncotarget.12760 · Cited by 63
Heparin-Degrading Sulfatases in Hepatocellular Carcinoma: Roles in Pathogenesis and Therapy Targets
Lai, J.-P., Thompson, J. R., Sandhu, D. S., & Roberts, L. R. (2008) · Future Oncology · doi:10.2217/14796694.4.6.803 · Cited by 59
Liang, J., Ding, T., Guo, Z.-W., Yu, X.-J., Hu, Y.-Z., Zheng, L., & Xu, J. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.390 · Cited by 58
Self-citationViviano, B. L., Silverstein, L., Pflederer, C., Paine‐Saunders, S., Mills, K., & Saunders, S. (2005) · Developmental Biology · doi:10.1016/j.ydbio.2005.03.003 · Cited by 56
Clinical Utility of Plasma Glypican-3 and Osteopontin as Biomarkers of Hepatocellular Carcinoma
Lee, H. J., Yeon, J. E., Suh, S. J., Lee, S.-J., Yoon, E. L., Kang, K., Yoo, Y. J., Kim, J. H., Seo, Y. S., Yim, H. J., et al. (2014) · Gut and Liver · doi:10.5009/gnl.2014.8.2.177 · Cited by 55
MicroRNA-1291-mediated silencing of IRE1α enhances Glypican-3 expression
Maurel, M., Dejeans, N., Taouji, S., Chevet, É., & Grosset, C. F. (2013) · RNA · doi:10.1261/rna.036483.112 · Cited by 55
Yu, J., Xu, X., Ma, R., Qin, S.-N., Wang, C.-R., Wang, X., Li, M., Li, M., Ma, Q., & Xu, W. (2014) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.21733 · Cited by 52
Molecular basis of differential target regulation by miR-96 and miR-182: the Glypican-3 as a model
Jalvy, S., Maurel, M., Majo, V., Pierre, N., Chabas, S., Combe, C., Rosenbaum, J., Sagliocco, F. A., & Grosset, C. F. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr843 · Cited by 52
Glypican-1 as a Biomarker for Prostate Cancer: Isolation and Characterization
Truong, Q., Justiniano, I., Nocon, A. L., Soon, J., Wissmueller, S., Campbell, D. H., & Walsh, B. J. (2016) · Journal of Cancer · doi:10.7150/jca.14645 · Cited by 52
Miao, H., Pan, Z., Lei, C., Wen, J., Li, M., Liu, Z., Qiu, Z., Lin, M., Chen, N., & Chen, M. (2012) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24404 · Cited by 50
Wang, S., Qiu, M., Xia, W., Xu, Y., Mao, Q., Wang, J., Dong, G., Xu, L., Yang, X., & Yin, R. H. (2016) · Oncotarget · doi:10.18632/oncotarget.12945 · Cited by 50
Nobuoka, D., Yoshikawa, T., Takahashi, M., Iwama, T., Horie, K., Shimomura, M., Suzuki, S., Sakemura, N., Nakatsugawa, M., Sadamori, H., et al. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1366-6 · Cited by 49
Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapy
Wang, C., Gao, W., Feng, M., Pastan, I. H., & Ho, M. (2016) · Oncotarget · doi:10.18632/oncotarget.10592 · Cited by 49
Yoo, H. J., Hwang, S. Y., Cho, G. J., Hong, H. C., Choi, H. Y., Hwang, T. G., Kim, S. M., Blüher, M., Youn, B., Baik, S. H., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4297 · Cited by 48
Manne, U., Weiss, H. L., & Grizzle, W. E. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20000920)89:5<418::aid-ijc4>3.0.co;2-i · Cited by 46
Yu, M. C., Lee, Y. S., Lin, S., Wu, H. Y., Chen, T. C., Lee, W.-C., Chen, M., & Tsai, C. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-011-1946-2 · Cited by 46
Motomura, Y., Ikuta, Y., Kuronuma, T., Komori, H., Ito, M., 昌巳, 土., Tsunoda, Y., Shirakawa, H., Baba, H., Nishimura, Y., et al. (2008) · International Journal of Oncology · doi:10.3892/ijo.32.5.985 · Cited by 44
García‐Suárez, O., García, B., Fernández‐Vega, I., Astudillo, A., & Quirós, L. M. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00015 · Cited by 42
Takai, H., Kato, A., Kato, C., Watanabe, T., Matsubara, K., Suzuki, M., & Kataoka, H. (2009) · Liver International · doi:10.1111/j.1478-3231.2008.01968.x · Cited by 41
Can Glypican3 be Diagnostic for Early Hepatocellular Carcinoma among Egyptian Patients?
Abdelgawad, I. A., Mossallam, G. I., Radwan, N. H., Elzawahry, H. M., & El-Hifnawi, N. M. (2013) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2013.14.12.7345 · Cited by 41
Sayem, M. A., Tomita, Y., Yuno, A., Hirayama, M., Irie, A., Tsukamoto, H., Senju, S., Yuba, E., Yoshikawa, T., Kono, K., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1062209 · Cited by 36
Zhang, Z. (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s32196 · Cited by 36
Silencing glypican-3 expression induces apoptosis in human hepatocellular carcinoma cells
Liu, S., Li, Y., Chen, W., Zheng, P., Liu, T., He, W., Zhang, J., & Zeng, X. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.02.069 · Cited by 36
Luo, R. (2011) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2011.704 · Cited by 31
Sawada, Y., Yoshikawa, T., Fujii, S., Mitsunaga, S., Nobuoka, D., Mizuno, S., Takahashi, M., Yamauchi, C., Endo, I., & Nakatsura, T. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.24179 · Cited by 30
Liu, X.-F., Hu, Z.-D., Liu, X., Cao, Y., Ding, C.-M., & Hu, C. (2013) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2013.12.007 · Cited by 27
Iwama, T., Uchida, T., Sawada, Y., Tsuchiya, N., Sugai, S., Fujinami, N., Shimomura, M., Yoshikawa, T., Zhang, R., Uemura, Y., et al. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.11.084 · Cited by 27
Liu, J.-W., Zuo, X.-L., & Wang, S. (2015) · PubMed · Cited by 25
Jia, X., Gao, Y., Zhai, D., Liu, J., Cai, J., Wang, Y., Li, J., & Zhi, D. (2015) · Technology in Cancer Research & Treatment · doi:10.1177/1533034615605248 · Cited by 25
Optimization of tissue processing for immunohistochemistry for the detection of human glypican-3
Takai, H., Kato, A., Ishiguro, T., et al. (2009) · Acta Histochemica · doi:10.1016/j.acthis.2008.11.025 · Cited by 24
Tumor-Associated Macrophage: Its Role in Tumor Angiogenesis
Lee, C.-C., Liu, K., & Huang, T. (2006) · Cited by 24
Takai, H., Kato, A., Kinoshita, Y., Ishiguro, T., Takai, Y., Ohtani, Y., Sugimoto, M., & Suzuki, M. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.10.8149 · Cited by 22
Glypican-1 as a highly sensitive and specific pancreatic cancer biomarker
Diamandis, E. P., & Plebani, M. (2015) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2015-0773 · Cited by 21
Iwama, T., Horie, K., Yoshikawa, T., Nobuoka, D., Shimomura, M., SAWADA, Y., & Nakatsura, T. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.1793 · Cited by 20
Glypican-4: role in insulin signalling
Mitchell, F. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.133 · Cited by 8
Cited by
Advances in the Early Diagnosis of Hepatocellular Carcinoma
Wang, W., & Wei, C. (2020) · Genes & Diseases · doi:10.1016/j.gendis.2020.01.014 · Cited by 492
Small-molecule fluorescence-based probes for interrogating major organ diseases
Han, H.-H., Tian, H., Zang, Y., Sedgwick, A. C., Li, J., Sessler, J. L., He, X.-P., & James, T. D. (2021) · Chemical Society Reviews · doi:10.1039/d0cs01183e · Cited by 366
Tumor Microenvironment: Extracellular Matrix Alterations Influence Tumor Progression
Brassart-Pasco, S., Brézillon, S., Brassart, B., Ramont, L., Oudart, J.-B., & Monboisse, J. C. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00397 · Cited by 335
HCCDB: A Database of Hepatocellular Carcinoma Expression Atlas
Lian, Q., Wang, S., Zhang, G., Wang, D., Luo, G., Tang, J., Chen, L., & Gu, J. (2018) · Genomics, Proteomics & Bioinformatics · doi:10.1016/j.gpb.2018.07.003 · Cited by 288
Metadata
- Authors
- Zhou, F., Shang, W., Yu, X., & Tian, J.
- Venue
- Medicinal Research Reviews
- Publisher
- Wiley
- Published
- 2017-06-16
- Volume
- 38
- Issue
- 2
- Pages
- 741-767
- ISSN
- 0198-6325 (ISSN-L)
- 1098-1128
- OpenAlex
- W2624710378
- Cited by
- 397
- References
- 125
- FWCI
- 10.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.